AOA

AOA Dx is a women’s health company developing technology for earlier cancer detection. Its team of industry experts and entrepreneurs aims to move impactful, cost-effective medical technologies from research and development into the hands of healthcare providers and patients. The company focuses on lipidomics, using lipid markers alongside complementary biomarkers and data science to support the discovery of insights for early cancer diagnosis.

AOA Dx’s GlycoLocate™ is an AI-enabled, multi-omics platform designed to advance early cancer detection. Its related offering, AKRIVIS GD™, is a blood test that uses artificial intelligence and multi-omics to detect early-stage ovarian cancer. Together, these initiatives reflect the company’s focus on applying emerging analytical approaches to unmet needs in women’s health.

AOA Dx also shares information about its technology, team, publications, and news, and invites people interested in its mission to explore career opportunities. Through its platform development and diagnostic work, the company is working to bring new approaches to early cancer detection closer to providers and patients.